ERVW-1 and neoplasm: Our study demonstrates for the first time that subtype-specific HERV-K102-Env is a novel immunosuppressive serum cancer biomarker that correlates with tumor markers and can be used to assess the state of immune dysfunction and the staging of cancer in cancer patients.